Published in Aging and Elder Health Week, June 19th, 2005
The achievement of this milestone will trigger an undisclosed payment to Cytos Biotechnology.
CAD106 treatment aims at the generation of antibodies against the beta-amyloid-protein that inhibit the formation of "plaques" involved in the Alzheimer disease process. CAD106 is the product of the collaborative program between Novartis and Cytos Biotechnology first...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging and Elder Health Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.